Latest Conference Articles

September 28, 2021

An analysis of NHANES data presented at EASD 2021 details the effects of returning to a healthy weight among patients with obesity compared to those currently with obesity and those who always maintained a healthy weight.

September 28, 2021

An analysis of patient data from a national registry in Denmark indicates use of alendronate was associated with reductions in odds of developing type 2 diabetes, with this reduction becoming greater with longer use of the osteoporosis medication.

September 27, 2021

A posthoc analysis of the REWIND trial is providing insight into the overall standard of care seen with women with diabetes and increased cardiovascular risk compared to their male counterparts with diabetes and increased cardiovascular risk.

July 07, 2021

Diana Isaacs, PharmD, offers perspective on her top 5 CGM-related studies or presentations from the American Diabetes Association's 81st Scientific Sessions.

July 02, 2021

Insights from the DISCOVER registry were presented at the American Diabetes Association's 81st Scientific Sessions. Check out our Q&A with study presenter Suzanne Arnold, MD, of St. Luke's Mid America Heart Institute.

June 30, 2021

Our editorial staff has selected a shortlist of highlighted data and summary slides on their picks of the most important data to be released at the American Diabetes Association's 81st Annual Scientific Sessions.

June 29, 2021

Data from the SURPASS program presented at ADA 2021 provide insight into the effects of tirzepatide on HbA1c control and body weight in a variety of different patient populations as both an add-on and monotherapy.

June 29, 2021

While still waiting for regulatory approval, the SCORED and SOLOIST trial have demonstrated the impact of sotagliflozin, a dual SGLT1/2 inhibitor, on patients with type 2 diabetes and chronic kidney disease or heart failure.

June 29, 2021

Using banked samples from the CANVAS trial, investigators demonstrate the ability of KidneyIntelX to monitor therapeutic response to SGLT2 inhibitors and predict disease progression in patients with type 2 diabetes and chronic kidney disease.

June 28, 2021

Data from the AMPLITUDE-O trial demonstrates the effects of the exendin-4-based GLP-1 RA efpeglenatide on cardiovascular and renal outcomes among patients with type 2 diabetes and cardiovascular disease or kidney disease.